Most Read Articles
Pearl Toh, 3 days ago
Not only does the CGRP* inhibitor galcanezumab show sustained efficacy in migraine patients, long-term treatment does not come with excess cardiovascular (CV) risk, according to studies presented at the AAN 2021 Annual Meeting.
01 Apr 2021
Migraine and headache are common ailments of people living in the modern era. Dr Jon Marshall of The Singapore Headache and Migraine Clinic shares his insights with Pearl Toh on how to manage migraine and headache using non-pharmaceutical strategies, with a focus on the manual medicine approach.
Tristan Manalac, 5 days ago
Visceral fat area is the strongest indicator of mobility disability among obese, community-dwelling, older adults, according to a recent Singapore study.
3 days ago
In a webinar held on 27 March 2021, paediatric endocrinology nurses Karen Blair, Kate Davies, and Siti Zarina Yaakop shared insights and clinical experience based on their frontline roles in caring for patients with central precocious puberty (CPP) and supporting their family members.

Bamlanivimab works in real-world COVID-19 patients

4 days ago

The use of the monoclonal antibody bamlanivimab for COVID-19 yields good results, cutting the incidence of hospitalization among patients treated in the real-world setting, as shown in a study.

The study population consisted of 218 patients who received bamlanivimab (cases) and 185 who were referred but did not receive the study drug (controls). All patients were adults, ambulatory, had risk factors for severe COVID-19, and referrals for bamlanivimab via emergency use authorization (EUA).

Compared with controls, patients treated with bamlanivimab were older (p=0.008), more likely to be immunosuppressed (odds ratio [OR], 1.68, 95 percent confidence interval [CI], 1.07–2.64; p=0.024), and had a greater proportion of those aged >55 years with chronic lung disease (OR, 2.19, 95 percent CI, 1.11–4.33; p=0.021). Gender distribution and rates of other comorbid conditions by EUA indication (body mass index, diabetes, chronic kidney disease, or >55 years with hypertension or cardiovascular disease) were similar.

The primary outcome of 30-day hospitalization rate was significantly lower in the treated than nontreated group (7.3 percent vs 20.0 percent; relative risk, 0.37, 95 percent CI, 0.21–0.64; p<0.001), and the number needed to treat was 8.

On multivariable logistic regression, factors predicting the incidence of hospitalization included nonreceipt of bamlanivimab (OR, 4.19, 95 percent CI, 1.31–2.16; p<0.001) and a higher number of prespecified comorbidities (OR, 1.68, 95 percent CI, 2.12–8.30; p<0.001).

The present data may aid in the identification of high-risk, ambulatory patients who should be considered for EUA monoclonal antibody treatment to prevent hospitalizations associated with severe COVID-19.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 3 days ago
Not only does the CGRP* inhibitor galcanezumab show sustained efficacy in migraine patients, long-term treatment does not come with excess cardiovascular (CV) risk, according to studies presented at the AAN 2021 Annual Meeting.
01 Apr 2021
Migraine and headache are common ailments of people living in the modern era. Dr Jon Marshall of The Singapore Headache and Migraine Clinic shares his insights with Pearl Toh on how to manage migraine and headache using non-pharmaceutical strategies, with a focus on the manual medicine approach.
Tristan Manalac, 5 days ago
Visceral fat area is the strongest indicator of mobility disability among obese, community-dwelling, older adults, according to a recent Singapore study.
3 days ago
In a webinar held on 27 March 2021, paediatric endocrinology nurses Karen Blair, Kate Davies, and Siti Zarina Yaakop shared insights and clinical experience based on their frontline roles in caring for patients with central precocious puberty (CPP) and supporting their family members.